FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Loannidou Sofia							Issuer Name and Ticker or Trading Symbol LogicBio Therapeutics, Inc. [LOGC] Date of Earliest Transaction (Month/Day/Year) 10/23/2018									ive title Otl		10%	Owner (specify
C/O LOGICBIO THERAPEUTICS, INC. 610 MAIN ST., 3RD FLOOR (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye						Execution Date,						rities Acquired (A) or ed Of (D) (Instr. 3, 4			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount		(A) or (D)	Price	Reported Transaction(s) Instr. 3 and 4)		(31. 4)		
Common Stock 10/23/201					2018	8		C		1,367,413		A	(1)	1,367,413		I		See Footnote ⁽²⁾	
Common Stock 10/23/201						8			P		420,000		A	\$10	1,787,413		B I		See Footnote ⁽²⁾
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	3. Transaction Date (Month/Day/Year)	Exec		4. Trans Code (In 8)				6. Date Exerci Expiration Da (Month/Day/\)		te Securities l		ities Unde	rlying ity (Instr. 3 an	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	ve ies sially ng ed	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title		Amount or Number of Shares		Transac (Instr. 4			
Series B Convertible Preferred Stock	(1)	10/23/2018			С	2,611,66		5 (1) (1)		(1)	Common Stock		1,367,41	\$0.00)	I	See Footnote ⁽²⁾	

Explanation of Responses:

- 1. Upon closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series B Convertible Preferred Stock.
- 2. The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.

Remarks:

/s/ Matthias Jaffe, as Attorneyin-Fact 10/25/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.